To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Expedited Access to Biosimilars Act. S. 1414. 119th
Cong., 1st
sess., Introduced in Senate April 10, 2025. https://www.govinfo.gov/app/details/BILLS-119s1414is.
APA
Congress, Senate (2025, April 10). Expedited Access to Biosimilars Act (S. 1414 (IS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119s1414is.
MLA
United States, Congress, Senate. Expedited Access to Biosimilars Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119s1414is. 119th Congress, S. 1414, Introduced in Senate 10 Apr. 2025.
Bluebook
S.1414 - 119th Congress (2025-2026): Expedited Access to Biosimilars Act, S.1414, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119s1414is.
